GlassScriptPhysician profile
Michael K Odonoghue
NPI 1194748962
$189,788.02
in general payments reported to CMS, 2019-2025
37 companies · $45K in 2025
The $45K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,150 · 2020: $8,178 · 2021: $2,126 · 2022: $32K · 2023: $60K · 2024: $33K · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $95K · Consulting Fee: $29K · Food and Beverage: $12K · Travel and Lodging: $3,324 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $94,650.00 |
| Consulting Fee | $28,860.00 |
| Food and Beverage | $11,559.48 |
| Travel and Lodging | $3,324.49 |
| Education | $107.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $138,642.12 | 2019-2025 | Aklief, Epsolay, Oracea |
| Organon LLC | $12,365.72 | 2024-2025 | Vtama, Hadlima |
| E.R. Squibb & Sons, L.L.C. | $9,400.91 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $4,306.03 | 2019-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $3,870.04 | 2020-2024 | Otezla |
| Incyte Corporation | $3,645.31 | 2022-2025 | Opzelura |
| Biofrontera INC. | $3,516.66 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Galderma Research & Development, LLC | $2,610.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $2,339.29 | 2019-2025 | |
| Abbvie INC. | $1,646.13 | 2019-2025 | |
| Pfizer INC. | $1,342.79 | 2019-2025 | |
| Dermavant Sciences, INC. | $1,076.78 | 2022-2024 | Vtama |
| Ucb, INC. | $1,050.38 | 2022-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $915.76 | 2019-2025 | Siliq, Cabtreo, Duobrii |
| Lilly USA, LLC | $679.86 | 2020-2025 | Taltz, Ebglyss, Olumiant |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Odonoghue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.